Regel Therapeutics uses targeted genome binding to restore gene expression in haploinsufficient disorders. The initial company focus is on neuronal and muscular diseases.
Menu
Regel Therapeutics uses targeted genome binding to restore gene expression in haploinsufficient disorders. The initial company focus is on neuronal and muscular diseases.